Luca Giani

Luca Giani is an investor and serial entrepreneur with a track record across venture creation, M&A, and translational science. He specializes in bridging science, strategy, capital, and talent to help build mission-driven ventures.

Luca was the Founder & CEO of Ilios Therapeutics, a neuroscience company developing a novel chemistry platform to address ALS, Parkinson’s, and Alzheimer’s disease. Under his leadership, Ilios has built a diversified preclinical pipeline, advanced lead optimization, filed foundational IP, and positioned the company for strategic partnerships.

Luca is a Termeer Fellow, part of a global network of emerging biotech CEOs mentored by industry leaders. He previously served as a Blavatnik Fellow in Life Science Entrepreneurship at Harvard Business School, and as a Technology and Public Purpose Fellow at Harvard’s Belfer Center, appointed by and working with former U.S. Secretary of Defense Ash Carter, where he authored policy work on accelerating treatments for neurodegenerative diseases under the mentorship of Dr. Robert Langer.

Earlier in his career, Luca co-founded Innbiotec Pharma; led international investments in MedTech and digital health 5Lion Ventures; and co-founded and commercialized Somnifix, a patented sleep apnea and snoring therapy. He began his career in M&A at Credit Suisse, followed by strategy consulting at Bain & Company in London, advising clients on market expansion, transformation, and operational optimization.

Luca holds an Master with Distinction from Harvard, has completed programs at Harvard Medical School, Harvard Business School, and MIT Sloan, and earned his B.S. magna cum laude from Georgetown University.